All Blogs

Jan 14, 2026

Vital Sign Monitoring Devices: Transforming Healthcare Through Continuous Patient Surveillance


Jan 13, 2026

Insilico Medicine Moves Garutadustat into Phase IIa Following First Patient Dosing; Sustained Therapeutics Reports Encouraging Phase 2 Outcomes for Long-Acting Non-Opioid Chronic Pain Drug; ZYUS Life Sciences Shares Early Results from Ongoing Phase 2a UTOPIA-1 Pain Trial; Merck Advances KRAS G12C Program With Phase 3 Calderasib Combination Study in NSCLC; Sanofi’s Teizeld Gains EU Approval for Early-stage Type 1 Diabetes


Jan 12, 2026

Chronic Hepatitis B: The Silent Epidemic Hiding in Plain Sight


Jan 09, 2026

Vitiligo Treatment Drug Pipeline Accelerates with Late-Stage Immune-Targeting Therapies



Jan 07, 2026

Top Home-Use Medical Devices Every Household Should Consider


Jan 06, 2026

Zenas BioPharma’s Obexelimab Delivers Positive Phase 3 Results in IgG4-RD; Sanofi Secures US Priority Review for Tzield in Pediatric Stage 2 Type 1 Diabetes; Axsome’s AXS-05 sNDA Accepted by FDA with Priority Review for Alzheimer’s Agitation; Vanda’s NEREUS Receives FDA Approval; Omeros’ YARTEMLEA Sets Milestone as First Approved TA-TMA Therapy


Jan 05, 2026

FDA Approves Omeros’ YARTEMLEA: A Breakthrough for Stem Cell Transplant Patients Facing TA-TMA


Jan 02, 2026

Is DLL3 Unlocking the New Code for the Neuroendocrine Cancers (NECs) Therapeutics’ Era?